Director of Xspray Pharma Picks Up 14% More Stock

Investors who take an interest in Xspray Pharma AB (publ) (STO:XSPRAY) should definitely note that the Director, Anders Bladh, recently paid kr45.74 per share to buy kr4.8m worth of the stock. That's a very solid buy in our book, and increased their holding by a noteworthy 14%.

View our latest analysis for Xspray Pharma

Xspray Pharma Insider Transactions Over The Last Year

In fact, the recent purchase by Anders Bladh was the biggest purchase of Xspray Pharma shares made by an insider individual in the last twelve months, according to our records. That implies that an insider found the current price of kr50.80 per share to be enticing. Of course they may have changed their mind. But this suggests they are optimistic. If someone buys shares at well below current prices, it's a good sign on balance, but keep in mind they may no longer see value. In this case we're pleased to report that the insider bought shares at close to current prices. Anders Bladh was the only individual insider to buy shares in the last twelve months.

Anders Bladh bought 340.29k shares over the last 12 months at an average price of kr41.53. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!

There are always plenty of stocks that insiders are buying. If investing in lesser known companies is your style, you could take a look at this free list of companies. (Hint: insiders have been buying them).

Insider Ownership Of Xspray Pharma

For a common shareholder, it is worth checking how many shares are held by company insiders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. It appears that Xspray Pharma insiders own 6.5% of the company, worth about kr112m. We've certainly seen higher levels of insider ownership elsewhere, but these holdings are enough to suggest alignment between insiders and the other shareholders.

What Might The Insider Transactions At Xspray Pharma Tell Us?

The recent insider purchase is heartening. And the longer term insider transactions also give us confidence. However, we note that the company didn't make a profit over the last twelve months, which makes us cautious. Once you factor in the high insider ownership, it certainly seems like insiders are positive about Xspray Pharma. Nice! In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Xspray Pharma. Every company has risks, and we've spotted 4 warning signs for Xspray Pharma (of which 2 don't sit too well with us!) you should know about.

Of course Xspray Pharma may not be the best stock to buy. So you may wish to see this free collection of high quality companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com